Using gene analysis to improve diagnosis of liver transplant rejection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory study aims to identify specific genes associated with acute rejection in liver transplant patients by analyzing biopsy samples. A panel of indicator genes related to both humoral and cell-mediated rejection will be selected from existing literature and applied to these samples. The study seeks to enhance molecular diagnostics to support traditional histological methods, potentially allowing for quicker and more accurate diagnosis of rejection. By identifying early cellular signals related to rejection, the study hopes to improve patient stratification and treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a diagnosis of post-OLT rejection prior to the visit at which they will be enrolled, with tissue available for RT-PCR investigations
* Age ≥ 18 years
* Informed consent

Exclusion Criteria:

* Age \<18 years

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Deborah Malvi, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Deborah Malvi, MD
• Email: deborah.malvi@aosp.bo.it
• Phone: 0512143761

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analyzing liver grafts to predict transplant outcomes

  This study is testing if certain markers in liver grafts can help predict how well the transplant will work for patients receiving the liver.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06717542

• Finding the right steroid dose for acute T cell rejection after kidney or kidney–pancreas transplant

  This trial will test whether lower doses of steroids work as well as higher doses to treat acute T cell–mediated rejection in people who have had a kidney or simultaneous kidney–pancreas transplant.

  Recruiting at 2 sites Phase 3 University of Sydney · Lambton, New South Wales and 29 other locations · NCT06474273

• Investigating white blood cells to develop new therapies for autoimmune diseases

  This study is trying to learn more about white blood cells from volunteers to help create new treatments for autoimmune diseases.

  Recruiting Quell Therapeutics Limited · London · NCT04838171

• Immune biomarkers to predict complications after liver transplantation

  This study tests immune biomarkers in adults after liver transplant to see if changes in markers relate to infections, rejection, or viral reactivation within the first year.

  Recruiting at 3 sites Hospital Italiano de Buenos Aires · Pilar, Buenos Aires and 2 other locations · NCT07875595

• Non-invasive test to predict early heart rejection in pediatric transplant patients

  This study tests non-invasive heart tests like cardiac MRI and blood markers to see if they can detect rejection in kids after heart transplant, potentially reducing the need for invasive biopsies.

  Recruiting at 22 sites Vanderbilt University Medical Center · Little Rock, Arkansas and 21 other locations · NCT07770659

• Multimodal prospective approach to understand acute and chronic lung transplant rejection

  This project will see if blood tests, airway sampling, imaging, and genetic analyses can identify which adults who have had or are being evaluated for a lung transplant will develop antibody‑mediated rejection and later chronic graft dysfunction.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07516379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.